NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) has been awarded first place in the Healthcare category at the BOLD Awards VII Gala, held March 27, 2026, in Barcelona. The recognition underscores the company's leadership in developing exosome-based therapies for central nervous system (CNS) injuries, a field with significant unmet medical need. The BOLD Awards, judged by a panel of global industry leaders, honor innovation and impact across various sectors, and NurExone's win positions it among top-tier healthcare innovators.
The company also provided a corporate update, announcing plans to engage Investor Brand Network (IBN), subject to TSX Venture Exchange approval, to support investor awareness efforts beginning April 1, 2026. Under a one-year agreement with a monthly fee of $6,500, IBN will distribute news and updates across more than 5,000 outlets. This engagement aims to strengthen market visibility and long-term shareholder value, as outlined in the full press release at https://ibn.fm/cWtqT.
NurExone is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on regenerative exosome-based therapies for CNS injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company has achieved regulatory milestones, including Orphan Drug Designation, which facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, NurExone is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. The company has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy, as detailed on its website at https://nurexone.com/.
The BOLD Awards recognition and planned investor outreach come at a pivotal time for NurExone, as it advances its pipeline toward clinical trials. The company's exosome-based approach represents a novel therapeutic modality for CNS injuries, which currently have limited treatment options. By leveraging IBN's extensive distribution network, NurExone aims to increase awareness among potential investors and partners, potentially accelerating its development timeline. The award also validates the company's scientific and strategic direction, as judged by international experts.
For further information, BioMedWire, a specialized communications platform focusing on biotechnology, biomedical sciences, and life sciences, has covered this development. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article syndication to 5,000+ outlets, and social media distribution. The platform is designed to help private and public companies reach a wide audience of investors, influencers, and the general public. More details about BioMedWire and its services are available at https://www.BioMedWire.com.
